CLINICAL CHARACTERISTICS OF BREAST CANCER WITH STEROID RECEPTORS EXPRESSION AND HER2 AMPLIFICATION

Since the  middle of the  previous  century  the  heterogeneity of breast cancer  became absolutely evident. This assumption was historically based on differences in clinical behavior and sensitivity to therapy. Treatment approach nowadays is based  primarily on clinical and morphological prognostic and predictive markers. Among morphologically derived markers the most  important are estrogen and progesterone receptors and HER2. Interestingly that tumors with expression of estrogen receptors and/or progesterone receptors that  showed also hyperexpression or amplification of HER2 have very poor outcome and low sensitivity to  all therapeutic  approaches.  Therefore we  want   to  summarize the  existing  clinical information that  is relevant to this topic.

1. Ганцев Ш.Х., Давыдов М.И. Аксиллярный лимфатический аппарат при раке молочной железы. Атлас: изд. 2-е дополн. с переводом на англ. яз. М.: МИА, 2011. С. 193: ил.

2. Andrulis I.L., Bull S.B., Blackstein M.E et al. neu/ erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. // J Clin Oncol. 1998. Vol. 16(4). P. 1340-1349.

3. Badve S., Nakshatri H. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications // J Clin Pathol. 2009. Vol. 62(1). P. 6-12.

4. Baselga J., Bradbury I., Eidtmann H., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial // Lancet. 2012. Vol. 379(9816). P. 633-640.

5. Benz C.C., Scott G.K., Sarup J.C. et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu // Breast Cancer Res Treat. 1992. Vol. 24(2). P. 85-95.

6. Berns E.M., Foekens J.A., van Staveren I.L., et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment // Gene. 1995. Vol. 159(1). P. 11-18.

7. Bhargava R., Dabbs D.J., Beriwal S., et al. Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer // Mod Pathol. 2011. Vol. 24(3). P. 367-374.

8. Blows F.M., Driver K.E., Schmidt M.K., et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies // PLoS Med. 2010. Vol. 7(5). P. 1000-1279.

9. Burstein H.J., Harris L.N., Marcom P.K. et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm // J Clin Oncol. 2003. Vol. 21(15). P. 2889-2895.

10. Carey L.A., Dees E.C., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes // Clin Cancer Res. 2007. Vol. 13(8). P. 2329-2334.

11. Charpin C., Garcia S., Bouvier C., et al. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients’ overall and disease-free survival // Br J Cancer.-1997. Vol. 75(11). P. 1667-1673.

12. Cheang M.C., Chia S.K., Voduc D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer // J Natl Cancer Inst. 2009. Vol. 101(10). P. 736-750.

13. Cheang M.C., Chia S.K., Voduc D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer // J Natl Cancer Inst. 2009. Vol. 101(10). P. 736-750.

14. Cheang M.C., Voduc D., Bajdik C., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype // Clin Cancer Res. 2008. Vol. 14(5). P. 1368-1376.

15. Comprehensive molecular portraits of human breast tumours // Nature. 2012. Vol. 490(7418). P. 61-70.

16. Coussens L., Yang-Feng T.L., Liao Y.C., et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene // Science. 1985. Vol. 230(4730). P. 1132-1139.

17. De Laurentiis M., Arpino G., Massarelli E., et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer // Clin Cancer Res. 2005. Vol. 11(13). P. 4741-4748.

18. Dowsett M. Estrogen receptor: methodology matters // J Clin Oncol. -2006. Vol. 24(36). P. 5626-5628.

19. Dowsett M., Ebbs S.R., Dixon J.M., et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer a study from the IMPACT trialists // J Clin Oncol. 2005. Vol. 23(11). P. 2477-2492.

20. Elledge R.M., Green S., Pugh R., et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study // Int J Cancer. 2000. Vol. 89(2). P. 111-117.

21. Ellis M.J., Tao Y., Young O., et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole // J Clin Oncol. 2006. Vol. 24(19). P. 3019-3025.

22. Gianni L., Pienkowski T., Im Y.H., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial // Lancet Oncol. 2012. Vol. 13(1). P. 25-32.

23. Goldhirsch A., Ingle J.N., Gelber R.D., et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 // Ann Oncol. 2009. Vol. 20(8). P. 1319-1329.

24. Guarneri V., Frassoldati A., Bottini A., et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study // J Clin Oncol. 2012. Vol. 30(16). P. 1989-1995.

25. Gutierrez M.C., Detre S., Johnston S., et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase // J Clin Oncol. 2005. Vol. 23(11). P. 2469-2476.

26. Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer // J Clin Oncol. 1999. Vol. 17(5). P. 1474-1481.

27. Houston S.J., Plunkett T.A., Barnes D.M., et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer // Br J Cancer. 1999. Vol. 79(7-8). P. 1220-1226.

28. Hudis C.A. Trastuzumab--mechanism of action and use in clinical practice // N Engl J Med. 2007. Vol. 357(1). P. 39-51.

29. Jensen E.V., Desombre E.R., Hurst D.J., et al. Estrogen-receptor interactions in target tissues // Arch Anat Microsc Morphol Exp. 1967. -Vol. 56(3). P. 547-569.

30. Johnston S.R. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations // Clin Cancer Res. 2005. Vol. 11(2 Pt 2). P. 889-899.

31. Johnston S.R., Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory // Nat Rev Cancer. 2003. Vol. 3(11). P. 821-831.

32. Kaufman B., Mackey J.R., Clemens M.R., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study // J Clin Oncol. 2009. Vol. 27(33). P. 5529-5537.

33. Konecny G., Pauletti G., Pegram M., et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer // J Natl Cancer Inst. 2003. Vol. 95(2). P. 142-153.

34. Kurokawa H., Arteaga C.L. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer // Clin Cancer Res. 2001. Vol. 7(12 Suppl). P. 4436-4442.

35. Liedtke C., Mazouni C., Hess K.R., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer // J Clin Oncol. 2008. Vol. 26(8). P. 1275-1281.

36. Lipton A., Ali S.M., Leitzel K., et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer // J Clin Oncol. 2002. Vol. 20(6). P. 1467-1472.

37. Lipton A., Ali S.M., Leitzel K., et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen // J Clin Oncol.-2003. Vol. 21(10). P. 1967-1972.

38. Long B.J., Jelovac D., Thiantanawat A., Brodie A.M. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model // Clin Cancer Res. 2002. Vol. 8(7). P. 2378-2388.

39. Marcom P.K., Isaacs C., Harris L., et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers // Breast Cancer Res Treat. 2007. Vol. 102(1). P. 43-49.

40. Marty M., Cognetti F., Maraninchi D., Snyder R. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group // J Clin Oncol. 2005. Vol. 23(19). P. 4265-4274.

41. Mittendorf E.A., Wu Y., Scaltriti M., et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes // Clin Cancer Res. 2009. Vol. 15(23). P. 7381-7388.

42. Nahta R., O’Regan R.M. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers // Breast Cancer Res Treat.-2012. Vol. 135(1). P. 39-48.

43. Nahta R., O’Regan R.M. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers // Breast Cancer Res Treat. 2012. Vol. 135(1). P. 39-48.

44. O’Malley F.P., Saad Z., Kerkvliet N. et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer // Hum Pathol. 1996. Vol. 27(9). P. 955-963.

45. Osborne C.K. Tamoxifen in the treatment of breast cancer // N Engl J Med. 1998. Vol. 339 (22). P. 1609-1618.

46. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours // Nature. 2000. Vol. 406(6797). P. 747-752.

47. Pietras R.J., Arboleda J., Reese D.M., et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells // Oncogene. 1995. Vol. 10(12). P. 2435-2446.

48. Press M.F., Bernstein L., Thomas P.A., et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas // J Clin Oncol. 1997. -Vol. 15(8). P. 2894-2904.

49. Press M.F., Pike M.C., Chazin V.R., et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease // Cancer Res. 1993. Vol. 53(20). P. 4960-4970.

50. Ravdin P.M., Green S., Dorr T.M., et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study // J Clin Oncol. 1992. Vol. 10(8). P. 1284-1291.

51. Rimawi M.F., Mayer I.A., Forero A., et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006 // J Clin Oncol. -2013. Vol. 31(14). P. 1726-1731.

52. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer // J Clin Oncol. 2006. Vol. 24(18). P. 2786-2792.

53. Sabnis G., Schayowitz A., Goloubeva O. et al. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen // Cancer Res. 2009. Vol. 69(4). P. 1416-1428.

54. Schneeweiss A., Chia S., Hickish T., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) // Ann Oncol. 2013.

55. Schnitt S.J. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy // Mod Pathol. 2010. Vol. 23. Suppl 2. P. 60-64.

56. Senkus E., Kyriakides S., Penault-Llorca F. et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol. – 2013.

57. Shou J., Massarweh S., Osborne C.K. et al.. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer // J Natl Cancer Inst. 2004. Vol. 96(12). P. 926-935.

58. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. // CA Cancer J Clin. 2013. Vol. 63(1). P. 11-30.

59. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 // N Engl J Med. 2001. Vol. 344(11). P. 783-792.

60. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets // Proc Natl Acad Sci U S A. 2003. Vol. 100(14). P. 8418-8423.

61. Stoica A., Saceda M., Doraiswamy V.L. et al. Regulation of estrogen receptor-alpha gene expression by epidermal growth factor // J Endocrinol. 2000. Vol. 165(2). P. 371-378.

62. Untch M., Fasching P.A., Konecny G.E., et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups // J Clin Oncol. 2011. Vol. 29(25). P. 3351-3357.

63. Untch M., Loibl S., Bischoff J. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial // Lancet Oncol.-2012. Vol. 13(2). P. 135-144.

64. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer // J Clin Oncol. 2002. Vol. 20(3). P. 719-726.

65. Vu T., Claret F.X. Trastuzumab: updated mechanisms of action and resistance in breast cancer // Front Oncol. 2012. Vol. 2. P. 62.

66. Wolff A.C., Dowsett M. Estrogen receptor: a never ending story? // J Clin Oncol. 2011. Vol. 29(22). P. 2955-2958.

67. Wright C., Nicholson S., Angus B., et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer // Br J Cancer. 1992. Vol. 65(1). P. 118-121.